ABSTRACT
Ectopic insulinoma is a very rare and dormant tumor. Here we report the case of a 79-year-old female who presented with repeated episodes of hypoglycemia and was diagnosed with insulinoma based on laboratory and imaging examinations. Computed tomography and positron emission tomography revealed a tumor in the retroperitoneum under and left of the hepatoduodenal ligament, which was resected successfully using a laparoscopic approach. Pathologic results revealed an ectopic insulinoma, which was confirmed immunohistochemically. Ectopic insulinomas are accompanied by hypoglycemia that can be misdiagnosed as drug- or disease-induced. These tumors are difficult to diagnose and locate, particularly in atypical cases or for very small tumors. Synthetic or targeted examinations, including low blood glucose, elevated insulin, proinsulin, and C-peptide levels, 48-h fasting tests, and relevant imaging methods should be considered for suspected cases of insulinoma. Surgery is the treatment of choice for patients with insulinoma, and laparoscopic resection is a feasible and effective method for select ectopic insulinoma cases.
Subject(s)
Choristoma/surgery , Insulinoma/surgery , Laparoscopy , Pancreatic Neoplasms , Retroperitoneal Neoplasms/surgery , Aged , Biomarkers, Tumor/analysis , Biopsy , Choristoma/diagnosis , Female , Humans , Immunohistochemistry , Insulinoma/chemistry , Insulinoma/pathology , Multimodal Imaging , Positron-Emission Tomography , Predictive Value of Tests , Retroperitoneal Neoplasms/chemistry , Retroperitoneal Neoplasms/diagnosis , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
As a noninvasive and label-free analytical technique, Raman spectroscopy has been widely used to study the difference between malignant cells and normal cells. Insulinomas are functional ß-cell tumors of pancreatic islet cells. They exhibit many structural and immunohistochemical features in common with normal pancreatic ß cells; thus, they are typically difficult to distinguish under the microscope, especially in vivo. We investigated insulinoma and primary rat pancreatic ß-cell populations using Raman spectroscopy. The details of the optical heterogeneity between these two populations were determined based on different Raman regions primarily involving nucleic acid and protein contents, which are the most distinct cellular contents in these two types of cells. Using principal component analysislinear discriminant analysis, these two cell types can be readily separated. The results of this work indicate that Raman spectroscopy is a promising tool for the noninvasive and label-free differentiation of insulinoma cells and normal pancreatic ß cells.
Subject(s)
Biomarkers, Tumor/analysis , Insulin-Secreting Cells/chemistry , Insulinoma/chemistry , Insulinoma/diagnosis , Molecular Imaging/methods , Spectrum Analysis, Raman/methods , Animals , Cell Line, Tumor , Diagnosis, Computer-Assisted/methods , Diagnosis, Differential , Pancreatic Neoplasms , Pattern Recognition, Automated/methods , Rats , Rats, Sprague-Dawley , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
BACKGROUND: Pancreatic neuroendocrine tumours (pNET) are relatively uncommon, accounting for 1-2% of all pancreatic neoplasms. They are characterised by varying clinical presentation, tumour biology and prognosis. AIM: To provide an updated overview on clinicopathological features, treatment and outcome of pNET. PATIENTS AND METHODS: In our retrospective study, we reviewed 9 cases of pNET that were diagnosed at the Pathology Department of Mongi Slim Hospital over an 11-year period (2003- 2013). Relevant clinical information and microscopic slides were available in all cases and were retrospectively reviewed. The latest WHO classification (2010) was adopted. RESULTS: Our study group included 3 men and 6 women (M/F ratio 0.5) with an age between 20 and 75 years (mean = 52 years). Pancreatic neuroendocrine tumours ranged in size from 0.5 to 10 cm (mean 4 cm). The sites of pNET were the head of the pancreas (n = 4), the body of the pancreas (n = 3) and the tail of the pancreas (n = 2). Enucleation of the tumour was performed in five cases, Three patients underwent distal pancreatectomy and splenectomy, whereas only one patient had central pancreatectomy. Histopathological examination of the surgical specimen coupled with immunohistochemical study established a diagnosis of pNET grade 1 (G1) in seven cases and grade 2 (G2) in two cases. CONCLUSION: Pancreatic neuroendocrine tumours are a heterogeneous group of neoplasms with distinct tumour genetics, biology and clinicopathological features. Accurate clinical and pathologic diagnosis is an important first step in developing an appropriate management plan.
Subject(s)
Insulinoma/pathology , Pancreatic Neoplasms/pathology , Adult , Aged , Biomarkers, Tumor/analysis , Biopsy , Female , Humans , Immunohistochemistry , Insulinoma/chemistry , Insulinoma/surgery , Male , Middle Aged , Neoplasm Grading , Pancreatectomy , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/surgery , Retrospective Studies , Splenectomy , Time Factors , Tomography, X-Ray Computed , Treatment Outcome , Tumor Burden , Tunisia , Young AdultABSTRACT
Neuroendocrine regulatory peptides NERP-1 and NERP-2 are novel amidated peptides derived from VGF, a polypeptide secreted from neurons and endocrine cells through a regulated pathway. To explore the localization of NERPs in human tissues, we performed immunohistochemistry analysis on tissues obtained at autopsy or surgery. In the hypothalamus, cell bodies that stained strongly for NERPs were observed in the supraoptic and paraventricular nucleus where vasopressin was abundant. Immunoreactive (ir) NERPs were detected in the islets of the pancreas, where they colocalized extensively with insulin, partially with glucagon, and not at all with somatostatin. Ir-NERPs were also detected in the thyroid and gastric antrum, where they colocalized with calcitonin and gastrin, respectively. NERPs are colocalized with insulin in an insulinoma specimen. NERPs are abundant in the pancreas, and the tissue contents of ir-NERP-1 and -2 in the pancreas were 4.5+/-2.2 and 1.0+/-0.3 pmol/g wet tissue, respectively. NERPs were also detected in the thyroid and gastric antrum. Ir-NERPs of the human pancreas, thyroid and gastric antrum behaved identically to synthetic human NERP-1 or -2 on reverse phase-high performance liquid chromatography combined with radioimmunoassay. These results suggested that NERPs might function as local modulators in the human neuroendocrine system.
Subject(s)
Insulinoma/chemistry , Nerve Tissue Proteins/analysis , Pancreas/chemistry , Pyloric Antrum/chemistry , Thyroid Gland/chemistry , Chromatography, High Pressure Liquid , Humans , Immunohistochemistry , RadioimmunoassayABSTRACT
Recent investigations have demonstrated an influence of melatonin on insulin secretion in pancreatic beta-cells. The effects are receptor-mediated via two parallel signaling pathways. The aim of this study was to examine the relevance of a second melatonin receptor (MT2) as well as the involvement of a third signaling cascade in mediating melatonin effects, i.e. the cyclic guanosine monophosphate (cGMP) pathway. Our results demonstrate that the insulin-inhibiting effect of melatonin could be partly reversed by preincubation with the unspecific melatonin receptor antagonist luzindole as well as by the MT2-receptor-specific antagonist 4P-PDOT (4-phenyl-2-propionamidotetraline). As melatonin is known to modulate cGMP concentration via the MT2 receptor, these data indicate transmission of the melatonin effects via the cGMP transduction cascade. Molecular investigations established the presence of different types of guanylate cyclases, cGMP-specific phosphodiesterases and cyclic nucleotide-gated channels in rat insulinoma beta-cells (INS1). Moreover, variations in mRNA expression were found when comparing day and night values as well as different states of glucose metabolism. Incubation experiments provided evidence that 3-isobutyl-1-methylxanthine (IBMX)-stimulated cGMP concentrations were significantly decreased in INS1 cells exposed to melatonin for 1 hr in a dose- and time-dependent manner. This effect could also be reversed by application of luzindole and 4P-PDOT. Stimulation with 8-Br-cGMP resulted in significantly increased insulin production. In conclusion, it could be demonstrated that the melatonin receptor subtype MT2 as well as the cGMP signaling pathway are involved in mediating the insulin-inhibiting effect of melatonin.
Subject(s)
Cyclic GMP/metabolism , Insulin-Secreting Cells/metabolism , Insulin/metabolism , Melatonin/pharmacology , Receptor, Melatonin, MT2/metabolism , Signal Transduction , 1-Methyl-3-isobutylxanthine/pharmacology , Animals , Brain/metabolism , Cell Line, Tumor , Colforsin/pharmacology , Cyclic GMP/analogs & derivatives , Cyclic GMP/pharmacology , Cyclic Nucleotide Phosphodiesterases, Type 2/metabolism , Cyclic Nucleotide-Gated Cation Channels/metabolism , Diabetes Mellitus, Type 2 , Dose-Response Relationship, Drug , Glucose/metabolism , Guanylate Cyclase/metabolism , Insulin Secretion , Insulin-Secreting Cells/drug effects , Insulinoma/chemistry , Melatonin/metabolism , Pineal Gland/chemistry , Rats , Rats, Wistar , Receptor, Melatonin, MT2/antagonists & inhibitors , Tetrahydronaphthalenes/pharmacology , Tryptamines/pharmacologyABSTRACT
BACKGROUND: It is difficult to predict the biologic behavior of pancreatic endocrine tumors in absence of metastases or invasion into adjacent organs. The World Health Organization (WHO) has proposed in 2004 size, angioinvasion, mitotic activity, and MIB1 proliferation index as prognostic criteria. Our aim was to test retrospectively the predictive value of these 2004 WHO criteria and of CK19, CD99, COX2, and p27 immunohistochemistry in a large series of patients with long-term follow-up. DESIGN: The histology of 216 pancreatic endocrine tumor specimens was reviewed and the tumors were reclassified according to the 2004 WHO classification. The prognostic value of the WHO classification and the histopathologic criteria necrosis and nodular fibrosis was tested in 113 patients. A tissue microarray was constructed for immunohistochemical staining. The staining results were scored quantitatively for MIB1 and semiquantitatively for CK19, COX2, p27, and CD99. The prognostic value of these markers was tested in 93 patients. RESULTS: The stratification of the patients into 4 risk groups according to the 2004 WHO classification was reliable with regard to both time span to relapse and tumor-specific death. In a multivariate analysis, the CK19 status was shown to be independent of the WHO criteria. By contrast, the prognostic significance of COX2, p27, and CD99 could not be confirmed. CONCLUSIONS: The 2004 WHO classification with 4 risk groups is very reliable for predicting both disease-free survival and the time span until tumor-specific death. CK19 staining is a potential additional prognostic marker independent from the WHO criteria for pancreatic endocrine tumors.
Subject(s)
Carcinoma, Islet Cell/diagnosis , Insulinoma/diagnosis , Keratin-19/analysis , Pancreatic Neoplasms/diagnosis , World Health Organization , 12E7 Antigen , Adolescent , Adult , Aged , Aged, 80 and over , Antigens, CD/analysis , Carcinoma, Islet Cell/chemistry , Carcinoma, Islet Cell/mortality , Carcinoma, Islet Cell/pathology , Carcinoma, Islet Cell/surgery , Cell Adhesion Molecules/analysis , Cyclooxygenase 2/analysis , Disease-Free Survival , Female , Fibrosis , Follow-Up Studies , Humans , Immunohistochemistry , Insulinoma/chemistry , Insulinoma/mortality , Insulinoma/pathology , Insulinoma/surgery , Kaplan-Meier Estimate , Male , Middle Aged , Necrosis , Neoplasm Invasiveness , Neoplasm Staging , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Predictive Value of Tests , Proportional Hazards Models , Recurrence , Reproducibility of Results , Retrospective Studies , Time Factors , Tissue Array Analysis , Treatment OutcomeABSTRACT
Over the last several decades, considerable research has focused on the development of cell encapsulation technology to treat a number of diseases, especially type 1 diabetes. One of the key advantages of cell encapsulation is that it permits the use of xenogenic tissue, particularly animal-derived cell lines. This is an attractive idea, because it circumvents the issue of a limited human organ supply. Furthermore, as opposed to whole islets, cell lines have a better proliferative capacity and can easily be amplified in culture to provide an endless supply of uniform cells. We have previously described a macroencapsulation device for the immunoisolation of insulin-secreting 1-cells. The aim of this work was to optimize the viability and insulin secretion of cells encapsulated within this device. Specifically, the effects of cell packing density and device membrane configuration were investigated. The results indicated that cell density plays an important role in the secretory capacity of the cells, with higher cell density leading to increased insulin secretion. Increasing the transport area of the capsule by modifying the membrane configuration also led to an improvement in the insulin output of the device.
Subject(s)
Aluminum Oxide/chemistry , Insulin-Secreting Cells/metabolism , Insulin/metabolism , Biocompatible Materials/chemistry , Capsules , Cell Line, Tumor , Cell Survival , Humans , Insulin/administration & dosage , Insulin/chemistry , Insulin Secretion , Insulin-Secreting Cells/chemistry , Insulinoma/chemistry , Insulinoma/metabolism , Insulinoma/pathology , Microscopy, Confocal , Nanotechnology , Technology, Pharmaceutical/instrumentation , Technology, Pharmaceutical/methodsABSTRACT
OBJECTIVES: Immunocytochemical staining for lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) is able to recognize lymphatic vessel endothelium and pancreatic endocrine cells (PETs). Pancreatic endocrine tumors were studied for LYVE-1 immunocytochemical staining compared with normal pancreatic islets to detect possible presence of LYVE-1 in PETs. METHODS: Twenty-five cases of primary and metastatic PETs were immunocytochemically stained for LYVE-1, including insulinomas, glucagonomas, somatostatinoma, pancreatic polypeptidomas, gastrinomas, and nonfunctioning tumors. With routinely formalin-fixed and paraffin-embedded tissues, LYVE-1 immunostaining was performed with polyclonal goat antihuman LYVE-1. RESULTS: All normal pancreatic islet cells were positive for LYVE-1, whereas 2 cases of 25 PETs, 1 each of gastrinoma and nonfunctioning tumor, were positive for LYVE-1, retaining immunocytochemical reactivity of islet cells. CONCLUSIONS: Normal pancreatic islets were positive for LYVE-1, whereas only 2 of 25 PETs were positive, suggesting that most PETs lost LYVE-1 or contained below detectable levels of LYVE-1. The presence of LYVE-1 in pancreatic islets and in some PETs may suggest structure-function relationship of LYVE-1/lymphatic vessel in hormone synthesis and secretion.
Subject(s)
Gastrinoma/chemistry , Glucagonoma/chemistry , Immunohistochemistry , Insulinoma/chemistry , Islets of Langerhans/chemistry , Pancreatic Neoplasms/chemistry , Somatostatinoma/chemistry , Vesicular Transport Proteins/analysis , Cytoplasm/chemistry , Down-Regulation , Gastrinoma/pathology , Glucagonoma/pathology , Humans , Insulinoma/pathology , Islets of Langerhans/pathology , Lymphatic Vessels/chemistry , Pancreatic Neoplasms/pathology , Somatostatinoma/pathologyABSTRACT
A line of double-transgenic mice that develop neoplasms arising primarily in the pancreas was established. In these mice, the oncogene SV40 T antigen (Tag) was detected in the pancreas with and without the control of Tet-on system. The transgenic mice that developed pancreatic tumors as early as 20 weeks of age showed hypoglycemia on a blood glucose test. Pathological and immunohistochemical characterizations demonstrated that the tumors belonged to neuroendocrine neoplasms arising from pancreatic islets. A change in IGFs/IGF-1R signaling pathway was detected using real-time PCR analysis. A potential association between the IGFs/IGF-1R system and SV40Tag was studied to further explain the cancerogenesis of the double-transgenic mice by Western blot analysis and immunoprecipitation experiments. The results suggest that a Tag transgenic mice model could be used to study the molecular mechanism of the tumorigenesis of islets.
Subject(s)
Disease Models, Animal , Insulinoma/genetics , Mice, Transgenic , Mice , Neuroendocrine Tumors/genetics , Pancreatic Neoplasms/genetics , Animals , Antigens, Polyomavirus Transforming/analysis , Antigens, Polyomavirus Transforming/metabolism , Blood Glucose/metabolism , Insulin Receptor Substrate Proteins , Insulinoma/chemistry , Insulinoma/pathology , Neuroendocrine Tumors/chemistry , Neuroendocrine Tumors/pathology , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/pathology , Phosphoproteins/metabolism , Somatomedins/metabolism , Tetracycline/pharmacologyABSTRACT
OBJECTIVE: Expression of ghrelin has been reported in pancreatic endocrine tumours, but data on ghrelin receptor protein expression are lacking. The aim of this study was to examine the ghrelin receptor, as well as ghrelin, in a selected series of these tumours, including multiple endocrine neoplasia 1 (MEN1) associated tumours, and to correlate data with clinical features including body mass index. DESIGN: Immunohistochemical detection of ghrelin and its receptor was performed on frozen tissue from 31 tumours: 9 MEN1 and 22 sporadic. Twenty tumours were analysed by quantitative PCR. Plasma ghrelin was assessed in 26 patients. RESULTS: Twenty-one (68%) of 31 tumours showed immunoreactivity for ghrelin (8/9 MEN1) and 19/20 expressed ghrelin mRNA. Ghrelin receptor protein was detected in 21/30 (70%) tumours (4/8 MEN1), and mRNA was detected in all analysed tumours. Insulinomas had significantly higher levels of receptor mRNA than other tumours. Five patients had elevated plasma ghrelin (> 2 SD above the control group mean). No significant difference in mean plasma ghrelin levels was found between patients (908 +/- 569 ng/l) and controls (952 +/- 164 ng/l). Mean BMI was 24.3 kg/m(2). There was no association between ghrelin or receptor expression and survival. CONCLUSIONS: We report the first immunohistochemical data on expression of the ghrelin receptor in pancreatic endocrine tumours: 70% of tumours in our material. Concomitant ghrelin and receptor expression was seen in 50% of tumours, indicating an autocrine loop. Ghrelin was expressed in 68% of tumours (8/9 MEN1). Despite frequent ghrelin expression, elevated circulating ghrelin is rare in these patients.
Subject(s)
Adenoma, Islet Cell/metabolism , Pancreatic Neoplasms/metabolism , Peptide Hormones/genetics , Receptors, G-Protein-Coupled/genetics , Adenoma, Islet Cell/blood , Adenoma, Islet Cell/chemistry , Adult , Aged , Aged, 80 and over , Body Mass Index , Chi-Square Distribution , Female , Gene Expression , Ghrelin , Humans , Immunohistochemistry , Insulinoma/chemistry , Insulinoma/metabolism , Male , Middle Aged , Multiple Endocrine Neoplasia Type 1/chemistry , Multiple Endocrine Neoplasia Type 1/metabolism , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/chemistry , Peptide Hormones/analysis , Peptide Hormones/blood , Receptors, G-Protein-Coupled/analysis , Receptors, Ghrelin , Survival RateABSTRACT
The biological effects of neurotensin (NT) are mediated by two distinct G protein-coupled receptors, NTS(1) and NTS(2). Although it is well established that neurotensin inhibits gastric acid secretion in man, the plasma membrane receptor mediating these effects has not been visualized yet. We developed and characterized a novel antipeptide antibody to the carboxy-terminal region of the human NTS(2) receptor. The cellular and subcellular distribution of NTS(2) receptors was evaluated in various human gastrointestinal tissues. Specificity of the antiserum was demonstrated by (1) detection of a broadband migrating at M(r) 90 000-100 000 in Western blots of membranes from NTS(2)-expressing tissues; (2) cell-surface staining of NTS(2)-transfected cells; (3) translocation of NTS(2) receptor immunostaining after agonist exposure; and (4) abolition of tissue immunostaining by preadsorbtion of the antibody with its immunizing peptide. In the gastrointestinal tract, NTS(2) receptor immunoreactivity was highly abundant in parietal cells of the gastric mucosa, in neuroendocrine cells of the stomach small and large intestine, and in cells of the exocrine pancreas. NTS(2) receptors were clearly located in the plasma membrane and uniformly present on nearly all target cells. The presence of NTS(2) receptors was rarely detected in human tumors. This is the first localization of NTS(2) receptors in human formalin-fixed, paraffin-embedded tissues at the cellular level. The abundant expression of low-affinity NTS(2) receptors on the plasma membrane of human parietal cells provides a morphological substrate for the direct inhibition of gastric acid secretion observed after i.v. administration of neurotensin.
Subject(s)
Cell Membrane/chemistry , Parietal Cells, Gastric/chemistry , Receptors, Neurotensin/analysis , Antibodies, Monoclonal/isolation & purification , Antibodies, Monoclonal/pharmacology , Blotting, Western/methods , Humans , Immunohistochemistry/methods , Insulinoma/chemistry , Intestines/chemistry , Male , Neurotensin/metabolism , Oligonucleotide Array Sequence Analysis , Paraffin Embedding , Protein Binding , Receptors, Neurotensin/genetics , Stomach Neoplasms/chemistryABSTRACT
Precise localization and diagnosis of pancreatic endocrine tumors (PETs) is important, because pancreatic PETs have different clinical and biological behavior and treatment modalities than do exocrine pancreatic tumors. In contrast to the much more common exocrine adenocarcinomas, cytologic studies of PET are relatively rare and many cytopathologists lack experience with the cytomorphologic features of these tumors.During the last 10 yr, endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has matured into an accurate, highly sensitive, and cost-effective modality for the preoperative localization of pancreatic PETs. This has resulted in an increased number of PETs first sampled as cytology specimens. This manuscript focuses on the cytomorphologic features most suggestive of pancreatic PETs, differential diagnosis, and diagnostic pitfalls of PETs. The technical development of EUS-guided FNA and the ancillary studies for pancreatic PETs are also reviewed. The data summarized in this review indicate that EUS-FNA is a valuable method in the recognition of pancreatic PETs and in most cases cytopathologists could reach a correct diagnosis of these tumors, including their hormone producing capability on aspirated cytologic material.
Subject(s)
Biopsy, Fine-Needle/methods , Carcinoma, Islet Cell/pathology , Endoscopy, Digestive System/methods , Insulinoma/pathology , Pancreatic Neoplasms/pathology , Ultrasonography/methods , Adenocarcinoma, Papillary/pathology , Biomarkers, Tumor/analysis , Carcinoma, Acinar Cell/pathology , Carcinoma, Islet Cell/chemistry , Carcinoma, Pancreatic Ductal/pathology , Diagnosis, Differential , Gastrinoma/chemistry , Gastrinoma/pathology , Glucagonoma/chemistry , Glucagonoma/pathology , Humans , Immunohistochemistry , Insulinoma/chemistry , Lymphoma/pathology , Pancreatic Neoplasms/chemistryABSTRACT
A novel approach is presented for the simultaneous identification and relative quantification of secreted peptides, particularly those that have been historically difficult to analyze in a concerted manner. Peptides exceeding 60 residues with various degrees of post-translational modification were identified on a liquid chromatographic time scale. The approach demonstrates high efficiency pattern-based recognition analysis of complex neuroendocrine peptide sets and enables rapid identification of biomarkers from biological material.
Subject(s)
Biomarkers, Tumor/analysis , Drug Evaluation, Preclinical/methods , Hormones/chemistry , Insulinoma/chemistry , Pancreatic Neoplasms/chemistry , Peptides/chemistry , Amino Acid Sequence , Animals , Cell Line, Tumor , Colforsin/pharmacology , Computer Simulation , Culture Media, Conditioned/chemistry , Insulinoma/pathology , Molecular Sequence Data , Pancreatic Neoplasms/pathology , Proteomics/methods , RatsABSTRACT
The increasing incidence of diabetes and the need to further understand its cellular basis has resulted in the development of new diagnostic and therapeutic techniques. Nonetheless, the quest to noninvasively ascertain beta-cell mass and function has not been achieved. Manganese (Mn)-enhanced MRI is presented here as a tool to image beta-cell functionality in cell culture and isolated islets. Similar to calcium, extracellular Mn was taken up by glucose-activated beta-cells resulting in 200% increase in MRI contrast enhancement, versus nonactivated cells. Similarly, glucose-activated islets showed an increase in MRI contrast up to 45%. Although glucose-stimulated Ca influx was depressed in the presence of 100 microM Mn, no significant effect was seen at lower Mn concentrations. Moreover, islets exposed to Mn showed normal glucose sensitivity and insulin secretion. These results demonstrate a link between image contrast enhancement and beta-cell activation in vitro, and provide the basis for future noninvasive in vivo imaging of islet functionality and beta-cell mass.
Subject(s)
Image Enhancement/methods , Insulin-Secreting Cells/metabolism , Magnetic Resonance Imaging/methods , Animals , Cell Line, Tumor , Cell Separation , Cells, Cultured , Dose-Response Relationship, Drug , Glucose/pharmacology , Insulin/metabolism , Insulin Secretion , Insulin-Secreting Cells/chemistry , Insulinoma/chemistry , Insulinoma/metabolism , Insulinoma/physiopathology , Islets of Langerhans Transplantation/methods , Male , Manganese/pharmacokinetics , Manganese/pharmacology , Mice , Mice, Inbred Strains , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/physiopathology , Rats , Rats, Inbred LewABSTRACT
Insulinoma is the most common pancreatic endocrine tumor, accounting for 40% of all pancreatic functional neoplasm, and is characterized by hypersecretion of insulin and hypoglycemia. Elective treatment for insulinomas is surgical enucleation. Medical therapy with diazoxide, followed by somatostatin analogues in some cases, may be necessary to treat the hypoglycemic symptoms. We report a case of a patient affected by metastatic insulinoma with severe hypoglycemia. After surgery, histopathology confirmed the presence of a malignant insulinoma with multiple metastases in the liver. Due to the persistence of hypoglycemia, the patient was started on octreotide LAR treatment, which determined a complete clinical remission with regression of the metastatic lesions in the liver after one year. Repeated CT scans 2 and 3 years after surgery confirmed the remission. To our knowledge, the complete regression of the disease in insulinomas treated with long-standing somatostatin analogue therapy has never been reported. Immunohistochemical analysis in tissue specimens showed a strong membrane immunoreactivity for somatostatin receptors type 2 (SSTR2) in both the primary nodule and the metastases. The capacity of somatostatin analogues to negatively regulate cell proliferation through indirect and direct mechanisms has been experimentally demonstrated. Furthermore, SSTR2 activation may exert pro-apoptotic effects in neoplastic cells. Thus, both mechanisms may have been responsible of the remission of the disease in this patient. This case underlies the potential impact of the treatment of pancreatic insulinomas with somatostatin analogues, and, if confirmed, the usefulness of SSTR determination in these neoplastic specimens.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Insulinoma/secondary , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Octreotide/therapeutic use , Pancreatic Neoplasms/chemistry , Receptors, Somatostatin/analysis , Adult , Apoptosis , Cell Proliferation , Female , Humans , Immunohistochemistry , Insulinoma/chemistry , Insulinoma/drug therapy , Insulinoma/pathology , Liver Neoplasms/chemistry , Liver Neoplasms/diagnosis , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Remission Induction , Tomography, X-Ray ComputedABSTRACT
p62 is a cellular protein that plays an adapter role in signal transduction pathways involved in such diverse biological functions as proliferation, differentiation, reaction to oxidative stress and immune response. Furthermore, p62 has recently been detected as a component of intracytoplasmic protein aggregates (inclusion bodies), which are hallmarks of a variety of chronic degenerative disorders, such as Parkinson's disease and Alzheimer's disease, but also of steatohepatitis. Here we report that p62 and insulin are co-expressed in a diffuse fashion in beta cells in normal human pancreas as well as in primary chronic pancreatitis and in normal pancreas from mouse and swine. In contrast, p62 protein is absent from, or only focally and very weakly expressed in, insulinomas, glucagonomas or non-functioning pancreatic neuroendocrine tumours or carcinomas that express insulin or other pancreatic as well as extrapancreatic hormones. Although the biological function of p62 in beta cells is unknown, the co-expression of p62 and insulin in non-neoplastic beta cells suggests that, in the beta cell, p62 may play a role in specific insulin-related signalling. Since p62 may also be involved in pro-apototic signal transduction, the loss of p62 expression in neuroendocrine neoplasms of the pancreas may render the tumour cells less sensitive to pro-apototic signals. Further research is necessary to elucidate the role of p62 in beta cell-specific signal transduction.
Subject(s)
Adaptor Proteins, Signal Transducing/analysis , Islets of Langerhans/chemistry , Pancreatitis/genetics , Animals , Antibodies, Neoplasm/immunology , Carcinoma, Neuroendocrine/chemistry , Carcinoma, Neuroendocrine/genetics , Chronic Disease , Cross Reactions/immunology , Female , Gene Expression/genetics , Glucagonoma/chemistry , Glucagonoma/genetics , Humans , Immunohistochemistry/methods , Insulinoma/chemistry , Insulinoma/genetics , Male , Mice , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/genetics , Sequestosome-1 Protein , SwineABSTRACT
There is little information available concerning the link between the ryanodine (RY) receptors and the downstream Ca(2+) signaling events in beta-cells. In fura-2 loaded INS-1E cells, activation of RY receptors by 9-methyl 5,7-dibromoeudistomin D (MBED) caused a rapid rise of [Ca(2+)]i followed by a plateau and repetitive [Ca(2+)]i spikes on the plateau. The [Ca(2+)]i plateau was abolished by omission of extracellular Ca(2+) and by SKF 96365. In the presence of SKF 96365, MBED produced a transient increase of [Ca(2+)]i, which was abolished by thapsigargin. Activation of RY receptors caused Ca(2+) entry even when the ER Ca(2+) pool was depleted by thapsigargin. The [Ca(2+)]i plateau was not inhibited by nimodipine or ruthenium red, but was inhibited by membrane depolarization, La(3+), Gd(3+), niflumic acid, and 2-aminoethoxydiphenyl borate, agents that inhibit the transient receptor potential channels. The [Ca(2+)]i spikes were inhibited by nimodipine and ryanodine, indicating that they were due to Ca(2+) influx through the voltage-gated Ca(2+) channels and Ca(2+)-induced Ca(2+) release (CICR). Activation of RY receptors depolarized membrane potential as measured by patch clamp. Thus, activation of RY receptors leads to coherent changes in Ca(2+) signaling, which includes activation of TRP-like channels, membrane depolarization, activation of the voltage-gated Ca(2+) channels and CICR.
Subject(s)
Calcium Channels/metabolism , Calcium Signaling/physiology , Ryanodine Receptor Calcium Release Channel/metabolism , Animals , Cell Line, Tumor , Insulinoma/chemistry , Insulinoma/metabolism , Insulinoma/pathology , Islets of Langerhans/chemistry , Islets of Langerhans/metabolism , Islets of Langerhans/pathology , Male , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Patch-Clamp Techniques/methods , Rats , Rats, WistarABSTRACT
BACKGROUND: 3-guanidinopropionic acid derivatives reduce body weight in obese, diabetic mice. We have assessed whether one of these analogues, the aminoguanidine carboxylate BVT.12777, opens KATP channels in rat insulinoma cells, by the same mechanism as leptin. RESULTS: BVT.12777 hyperpolarized CRI-G1 rat insulinoma cells by activation of KATP channels. In contrast, BVT.12777 did not activate heterologously expressed pancreatic beta-cell KATP subunits directly. Although BVT.12777 stimulated phosphorylation of MAPK and STAT3, there was no effect on enzymes downstream of PI3K. Activation of KATP in CRI-G1 cells by BVT.12777 was not dependent on MAPK or PI3K activity. Confocal imaging showed that BVT.12777 induced a re-organization of cellular actin. Furthermore, the activation of KATP by BVT.12777 in CRI-G1 cells was demonstrated to be dependent on actin cytoskeletal dynamics, similar to that observed for leptin. CONCLUSIONS: This study shows that BVT.12777, like leptin, activates KATP channels in insulinoma cells. Unlike leptin, BVT.12777 activates KATP channels in a PI3K-independent manner, but, like leptin, channel activation is dependent on actin cytoskeleton remodelling. Thus, BVT.12777 appears to act as a leptin mimetic, at least with respect to KATP channel activation, and may bypass up-stream signalling components of the leptin pathway.
Subject(s)
ATP-Binding Cassette Transporters/metabolism , Guanidines/pharmacology , Insulinoma/chemistry , Pancreatic Neoplasms/chemistry , Potassium Channels, Inwardly Rectifying/metabolism , Actins/metabolism , Animals , Cell Line, Tumor , Cytoskeleton/metabolism , Female , Injections/methods , Insulinoma/enzymology , Insulinoma/pathology , KATP Channels , Multidrug Resistance-Associated Proteins , Oocytes/metabolism , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/pathology , Phosphatidylinositol 3-Kinases/metabolism , Potassium Channels, Inwardly Rectifying/administration & dosage , RNA, Complementary/administration & dosage , Rats , Receptors, Drug , Sulfonylurea Receptors , Xenopus laevis/geneticsABSTRACT
Cell cycle dysregulation is one of the defining features of cancer. Cyclin-dependent kinase 4 (CDK4), together with its regulatory subunit cyclin D, governs cell cycle progression through the G1 phase. Cyclin-dependent kinase inhibitors, including p16(INK4A) (encoded by CDKN2A), in turn regulate CDK4. In particular, dysregulation of the p16/CDK4/cyclin D complex has been established in a variety of types of human tumours. Dominant activating mutations affecting codon 24 of the CDK4 gene (replacement of Arg24 by Cys or His) render CDK4 insensitive to p16(INK4) inhibition and are responsible for melanoma susceptibility in some kindreds. However, 'knock-in' mice homozygous for the CDK4(R24C) mutation were noted to develop multiple neoplasia, most commonly including endocrine tumours: pituitary adenomas, insulinomas and Leydig cell testicular tumours. We therefore speculated that sporadic human endocrine tumours might also harbour such mutations. The aim of the current study was to analyze the CDK4 gene for the two characterized activating mutations, R24C and R24H, in sporadic human pituitary adenomas, insulinomas and Leydig cell tumours. We used DNA extracted from 61 pituitary adenomas, and paired tumorous and neighboring normal genomic DNA extracted from 14 insulinoma and 6 Leydig cell tumour samples. Genomic DNA from patients with familial melanoma harbouring the R24C or the R24H mutations served as positive controls. All samples were subjected to PCR, mutation-specific restriction digests and/or sequencing. Both methodologies failed to detect mutations at these two sites in any of the sporadic endocrine tumours including pituitary adenomas, benign or malignant insulinomas or Leydig cell tumours, while the positive controls showed the expected heterozygote patterns. Protein expression of CDK4 was demonstrated by immunohistochemistry and Western blotting in pituitary and pancreatic samples. These data suggest that the changes in the regulatory 'hot-spot' on the CDK4 gene, causing various endocrine tumours in CDK4(R24C/R24C )mice, are not a major factor in sporadic pituitary, insulin beta-cell or Leydig cell tumorigenesis.